Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells

被引:14
作者
Chen, WS
Liu, JH
Liu, JM
Lin, JK
机构
[1] Natl Yang Ming Univ, Div Colorectal Surg, Taipei Vet Gen Hosp, Taipei 112, Taiwan
[2] Natl Hlth Res Inst, Taipei, Taiwan
[3] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Div Med Oncol, Taipei 112, Taiwan
关键词
5-fluorouracil; colorectal cancer; cyclooxygenase-2; inhibitor; drug interaction; irinotecan;
D O I
10.1097/00001813-200403000-00014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Selective cyclooxygenase-2 (COX-2) inhibitors have been found to induce anti-proliferative and apoptotic activity in many cancer cells. However, interaction between COX-2 inhibitors and other chemotherapeutic agents remains to be determined. We investigated the interactive effects of a selective COX-2 inhibitor, etodolac, in combination with 5-fluorouracil (5-FU) or SN-38 (active metabolite of irinotecan) on colon cancer cell lines, HT29 and SW620, in simultaneous and sequential administration schedules. Isobologram analysis demonstrated that etodolac in combination with 5-FU or SN-38 according to a simultaneous schedule resulted in only an additive effect; however, synergism was achieved in a sequential schedule. Apoptosis induction in both cell lines was also significantly increased after sequential treatment with etodolac followed by either 5-FU or SN-38 compared to that after simultaneous treatment with etodolac and either 5-FU or SN-38. Our study suggests apoptosis-inducing synergism resulted from administration of etodolac and either 5-FU or SN-38 sequentially, but not simultaneously. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 34 条
[1]  
Achiwa H, 1999, CLIN CANCER RES, V5, P1001
[2]   Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro [J].
Akutsu, M ;
Furukawa, Y ;
Tsunoda, S ;
Izumi, T ;
Ohmine, K ;
Kano, Y .
LEUKEMIA, 2002, 16 (09) :1808-1817
[3]  
ANCO S, 2002, J BIOL CHEM, V277, P27613
[4]   Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study [J].
Becerra, CR ;
Frenkel, EP ;
Asrfaq, R ;
Gaynor, RB .
INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (06) :868-872
[5]   Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor [J].
Chen, WS ;
Liu, JH ;
Wei, SJ ;
Liu, JM ;
Hong, CY ;
Yang, WK .
CANCER SCIENCE, 2003, 94 (03) :253-258
[6]  
Chen WS, 2001, INT J CANCER, V91, P894, DOI 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO
[7]  
2-#
[8]   NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines [J].
Cheng, JD ;
Imanishi, H ;
Amuro, Y ;
Hada, T .
INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (05) :755-761
[9]   The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells [J].
Elder, DJE ;
Halton, DE ;
Playle, LC ;
Paraskeva, C .
INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (03) :323-327
[10]  
Fujita T, 1998, CANCER RES, V58, P4823